<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883542</url>
  </required_header>
  <id_info>
    <org_study_id>sBOT</org_study_id>
    <nct_id>NCT03883542</nct_id>
  </id_info>
  <brief_title>Sub-type Specific Genomic Mutations in sBOTs</brief_title>
  <official_title>Sub-type Specific Genomic Mutations in Serous Borderline Ovarian Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify different origin in carcinogenesis between serous&#xD;
      borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c.&#xD;
      with invasive implants and d. with micropapillary pattern.&#xD;
&#xD;
      The presence of specific mutations could suggest for a more aggressive primary treatment if a&#xD;
      higher risk of recurrence can be expected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Borderline Ovarian Tumors (BOTs) behave indolently in the vast majority of cases&#xD;
      and the prognosis is usually favorable. There is more evidence that two subtypes of BOTs&#xD;
      represent a higher risk of recurrence or even progression to an invasive ovarian cancer. In&#xD;
      case of a presentation with a micro-papillary grow pattern or when invasive implants are&#xD;
      diagnosed the prognosis tend to be less favorable.&#xD;
&#xD;
      Genome sequencing in ovarian cancer helped to differentiate two different pathways in the&#xD;
      carcinogenesis.&#xD;
&#xD;
      Low grade serous carcinomas evolving from adenofibromas or borderline tumors over&#xD;
      non-invasive micropapillary serous borderline tumors to invasive micropapillary serous&#xD;
      carcinoma, show frequent mutations in the Kirsten Rat Sarcoma gene (KRAS), B-Raf Kinase&#xD;
      gene(BRAF), Erb-B2 Receptor Tyrosine Kinase 2 gene (ERBB2), Phosphatase and Tensin homolog&#xD;
      gene (PTEN), Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene&#xD;
      (PIK3CA) and Catenin Beta 1 gene (CTNNB1). This pathway is called Type I and is characterized&#xD;
      by a slow step-wise process. These low-grade invasive tumors are indolent and are known with&#xD;
      a better outcome than high-grade invasive tumors.&#xD;
&#xD;
      In contrast the Type II pathway development of invasive tumors is rapid and vast majority of&#xD;
      tumors show a Tumor Protein p53 (TP53) mutation and loss of Breast Cancer type 1&#xD;
      susceptibility protein (BRCA1).&#xD;
&#xD;
      The aim of this study is to identify different origin in carcinogenesis between serous&#xD;
      borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c.&#xD;
      with invasive implants and d. with micropapillary pattern.&#xD;
&#xD;
      The presence of specific mutations could suggest for a more aggressive primary treatment if a&#xD;
      higher risk of recurrence can be expected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genetic mutations</measure>
    <time_frame>2020</time_frame>
    <description>amount and type of genetic mutations in different subgroups will be analyzed and compared between the different subgroups. Are the mutations suggestive for a type I or type II pathway differentiation?</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Neoplasm Epithelial</condition>
  <arm_group>
    <arm_group_label>serous BOT</arm_group_label>
    <description>simple serous BOT ovarian tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serous BOT with non-invasive implants</arm_group_label>
    <description>BOT ovarian tissue presenting with non-invasive implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sBOT with micropapillary grow pattern</arm_group_label>
    <description>BOT ovarian tissue presenting with micropapillary grow pattern</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serous BOT with invasive implants</arm_group_label>
    <description>sBOT ovarian tissue presenting with invasive implants at the time of diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genomic mutations study</intervention_name>
    <description>Sequencing of the DNA samples extracted from the subgroups&#xD;
serous BOT tissue,&#xD;
serous BOT tissue with non-invasive implants and&#xD;
serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing&#xD;
Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)</description>
    <arm_group_label>sBOT with micropapillary grow pattern</arm_group_label>
    <arm_group_label>serous BOT</arm_group_label>
    <arm_group_label>serous BOT with invasive implants</arm_group_label>
    <arm_group_label>serous BOT with non-invasive implants</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Macrodissection of borderline ovarian tumor tissue. DNA extraction from paraffin embedded&#xD;
      material for genetic analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with proven serous bordeline ovarian tumors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Paraffin embedded material from the original borderline ovarian tumor must be present&#xD;
             and of good quality for DNA extraction.&#xD;
&#xD;
          -  Original slides are available for central pathological review.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of invasive ovarian carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stef cosyns, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZBrussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Cosyns, Dr</last_name>
    <phone>24776020</phone>
    <phone_ext>+32</phone_ext>
    <email>scosyns@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis UZBrussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Cosyns, Md</last_name>
      <phone>24776020</phone>
      <phone_ext>0032</phone_ext>
      <email>Scosyns@uzbrussel.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012 Mar;13(3):e103-15. doi: 10.1016/S1470-2045(11)70288-1. Review.</citation>
    <PMID>22381933</PMID>
  </reference>
  <reference>
    <citation>Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Review.</citation>
    <PMID>19700937</PMID>
  </reference>
  <reference>
    <citation>Despierre E, Lambrechts D, Neven P, Amant F, Lambrechts S, Vergote I. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010 May;117(2):358-65. doi: 10.1016/j.ygyno.2010.02.012. Epub 2010 Mar 7. Review.</citation>
    <PMID>20207398</PMID>
  </reference>
  <reference>
    <citation>Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79.</citation>
    <PMID>20154587</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Stefan Cosyns</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>low malignant potential</keyword>
  <keyword>serous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

